Mitsushige Sugimoto

Oita University
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (19)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Objectives Gastric cancer (GC) may be diagnosed after Helicobacter pylori eradication, sometimes with submucosal invasion; however, its clinical features on regular endoscopic surveillance remain unclear. This study evaluated invasive GC's characteristics after H. pylori eradication during regular endoscopic surveillance by comparing them with intramucosal cancers. Methods This retrospective multicenter study across 14 institutions between 2001 and 2022 evaluated patients with GC with submucosal or deeper invasion after surgical or endoscopic resection (invasive GC), compared to patients with intramucosal GC from high‐volume facilities. GC depth was analyzed using logistic regression (patient and mucosal factors as covariates), with significant factors explored in a subanalysis. Results In total, 116 of 413 patients with invasive GC and 189 of 545 with intramucosal GC were eligible for analysis. Invasive GC exhibited the following characteristics: (1) GC was a more common reason for H. pylori eradication (adjusted odds ratio [OR] 2.67; 95% confidence interval [CI] 1.25–5.69); (2) the upper third of the stomach was the more common site (OR 2.63; 95% CI 1.41–5.30); and (3) map‐like redness (MLR) could not be confirmed (OR 4.12; 95% CI 2.53–6.69). Subgroup analysis suggested that GC with less MLR occurred more often in younger females ( p < 0.004), showed antral intestinal metaplasia ( p < 0.001), and was common in undifferentiated or mixed‐type GC ( p < 0.001). Conclusions Characteristic findings of invasive GC during regular endoscopic surveillance after H. pylori eradication were associated with less MLR, along with H. pylori eradication due to GC and the upper gastric lesion locations.

Year:

2025

Background and Aim Helicobacter pylori infection rates and severity and susceptibility to gastric diseases vary widely in different populations because of different H. pylori strains, lifestyles, and genetic factors. South and Southeast Asia is a region where many ethnic groups are intermingled, and H. pylori strains have been shifting from Western‐type to East Asian‐type strains. We aimed to investigate the different endoscopic and histopathologic features in five South and Southeast Asian countries. Methods We examined differences in endoscopic and histopathological gastritis and H. pylori infection status in 2426 patients from South and Southeast Asian populations in Vietnam, Thailand, Myanmar, Bangladesh, and Nepal. Results Among Asian patients with abdominal symptoms, such as epigastric pain, nausea, abdominal discomfort, constipation, and heartburn, the prevalence of gastric disease, H. pylori infection status (current, past, and non‐infection), and severity of histopathological gastritis significantly differed between countries. Less than 10% of patients had atrophy and intestinal metaplasia, irrespective of country and H. pylori infection status; their severity when present was also mild. Although patients with gastric cancer had higher rates of atrophy and intestinal metaplasia compared with those with other diseases, half of them had no pathological atrophy or intestinal metaplasia. Conclusions Gastric condition and susceptibility to gastric disease differed among South and Southeast Asian populations. H. pylori infection rates remain high in Asian countries, but the frequency and severity of atrophy and gastric mucosal atrophy were low.

Year:

2025

Year:

2025

Delayed bleeding after endoscopic sphincterotomy (EST) constitutes a significant adverse event, occurring in ~0.5–5% of patients. The number of patients receiving anticoagulants to prevent cardiovascular and cerebrovascular disease has increased with the aging society worldwide; however, anticoagulants (direct oral anticoagulants [DOACs] and warfarin) are one of the most major risk factors for postprocedure bleeding. This review investigated post‐EST bleeding in anticoagulant users, focusing on risk factors, clinical guidelines, pharmacological characteristics, and the future of post‐EST bleeding. Several clinical guidelines for antithrombotic drug users have been established to prevent postprocedure bleeding; nevertheless, the risk of bleeding is believed to be several times higher than for nondrug users, regardless of clinical guideline compliance. The major problem in this field is that patients who experience delayed bleeding are often receiving multiple antithrombotic drugs, and no parameters that can accurately monitor the anticoagulant effect of DOACs have been identified. Therefore, identifying patients with a generally high‐risk of postprocedure bleeding is crucial. Recently, the plasma level and antifactor Xa activity of factor Xa inhibitors have been investigated in relation to the risk of major bleeding in users. Similar to the prothrombin time‐international normalized ratio for warfarin, plasma levels, and antifactor Xa activity may be useful parameters for monitoring the anticoagulant effect and identifying DOAC users at higher risk of postprocedure bleeding, including post‐EST bleeding. Future studies should stratify the risk of post‐EST delayed bleeding based on a scoring system to prevent this complication.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (9)

Emiko Rimbara

National Institute of Infectious Diseases

JAPAN
View details

Kento Shionoya

Tokyo Medical and Dental University

JAPAN
View details

Junko Mukohyama

Lecturer

International University of Health and Welfare Mita Hospital

JAPAN
View details

Takashi Kawai

-

JAPAN
View details

Soichiro Sue

Assistant professor

Yokohama Kokuritsu Daigaku

JAPAN
View details

Yosuke Toya

Iwate Medical University

JAPAN
View details

Takeshi Kanno

Specially Appointed Professor

Jichi Medical University

JAPAN
View details

Takako Osaki

Kyorin University

JAPAN
View details

Mitsuhiro Fujishiro

Professor

Nagoya University

JAPAN
View details